The Pattern of Hair Dyeing in Koreans with Gray Hair

Background: Hair graying is considered as a part of normal ageing process. Nonetheless, this process raises a significant cosmetic concern, especially among ethnic Korean elderly whose baseline hair color is black. For this reason, Korean elderly dye their hair with frequency despite the risk of dermatologic problems such as allergic contact dermatitis. Objective: In this study, the authors investigate the prevalence and pattern of hair dyeing and its relation with scalp diseases in Korea. Methods: Six hundred twenty subjects (330 men and 290 women) with graying hair were given a questionnaire survery and underwent a physical examination. Results: Of the 620 total, 272 subjects (43.9%) dyed their hair. Hair dyeing was significantly more frequent among women than among men (p<0.001). Subjects from 50 to 69 years of age showed higher prevalence of hair dyeing when compared to either younger or older groups. Subjective self-assessment of the extent of hair graying was associated with increased prevalence of hair dyeing, that is, individuals who feel graying has advanced by more than 20% of the overall hair were much more likely to dye their hair (p<0.001). Hair dyeing did not correlate with either alopecia or scalp disease. Conclusion: Our survey has found that the prevalence of hair dyeing is higher among Korean women than men. People in their fifties and sixties and people with more than 20% extent of grayness were more likely to dye their hair than otherwise. Hair dyeing was not associated with any increase in the prevalence of scalp diseases.OAIID:oai:osos.snu.ac.kr:snu2013-01/102/2008000790/16SEQ:16PERF_CD:SNU2013-01EVAL_ITEM_CD:102USER_ID:2008000790ADJUST_YN:YEMP_ID:A079501DEPT_CD:801CITE_RATE:.611FILENAME:hair dyeing pattern in koreans.pdfDEPT_NM:의학과CONFIRM:

Efficacy and Safety of Pueraria lobata Extract in Gray Hair Prevention: A Randomized, Double-Blind, Placebo-Controlled Study

Background: Graying of hair?a sign of aging?raises cosmetic concerns. Individuals with gray hair often look older than others their age; therefore, some dye their hair for aesthetic purposes. However, hair colorants can induce many problems including skin irritation, allergic reaction and hair-breakage. Objective: This randomized, double-blind clinical trial was performed in order to examine the effects of APHG-1001, a compound including an extract from Pueraria lobata, on graying hair. Methods: A total of 44 female subjects were randomly treated with either APHG-1001 or placebo twice daily for 24 weeks. Using the phototrichogram analysis, a count of newly developed gray hair was estimated. Investigator assessment and subject self-assessment were also performed in order to evaluate the efficacy of the compound. Results: The mean number of newly developed gray hair at 24 weeks was 6.3/cm2 in the APHG-1001 group and 11.4/cm2 in the placebo group; the difference was statistically significant (p＜0.05). However, the investigator assessment and subject self-assessment did not show any significant change in the gross appearance of hair grayness by the end of the study. No severe adverse events in either group were observed. Moreover, the incidence of adverse events did not differ between the groups. Conclusion: This clinical trial revealed that APHG- 1001, which contains an extract of P. lobata, could prevent the development of new gray hair without any remarkable adverse effects. Thus, it can be considered as a viable treatment option for the prevention of gray hair. (Ann Dermatol 25(2) 218∼222, 2013)OAIID:oai:osos.snu.ac.kr:snu2013-01/102/0000045457/3SEQ:3PERF_CD:SNU2013-01EVAL_ITEM_CD:102USER_ID:0000045457ADJUST_YN:NEMP_ID:A079130DEPT_CD:801CITE_RATE:.531FILENAME:jo sj, et al ann dermatol 2013.pdfDEPT_NM:의학과EMAIL:[email protected]_YN:YCONFIRM:

Induction of transforming growth factor-beta 1 by androgen is mediated by reactive oxygen species in hair follicle dermal papilla cells

The progression of androgenetic alopecia is closely related toandrogen-inducible transforming growth factor (TGF)-β1 secretionby hair follicle dermal papilla cells (DPCs) in bald scalp.Physiological levels of androgen exposure were reported toincrease reactive oxygen species (ROS) generation. In thisstudy, rat vibrissae dermal papilla cells (DP-6) transfected withandrogen receptor showed increased ROS production followingandrogen treatment. We confirmed that TGF-β1 secretion isincreased by androgen treatment in DP-6, whereas androgeninducibleTGF-β1 was significantly suppressed by the ROSscavenger,N-acetyl cysteine. Therefore, we suggest that inductionof TGF-β1 by androgen is mediated by ROS in hair follicleDPCs.This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant No. A103017) and partially by a research agreement with AmorePacific Corporation, Republic of Korea.OAIID:oai:osos.snu.ac.kr:snu2013-01/102/0000045457/8SEQ:8PERF_CD:SNU2013-01EVAL_ITEM_CD:102USER_ID:0000045457ADJUST_YN:NEMP_ID:A079130DEPT_CD:801CITE_RATE:1.634FILENAME:(460-464)bmb 12-228.pdfDEPT_NM:의학과EMAIL:[email protected]_YN:YCONFIRM:

RETOS: Resilient, expandable, and threaded operating system for wireless sensor networks

This paper presents the design principles, implementation, and evaluation of the RETOS operating system which is specifically developed for micro sensor nodes. RETOS has four distinct objectives, which are to provide (1) a multithreaded programming interface, (2) system resiliency, (3) kernel extensibility with dynamic reconfiguration, and (4) WSN-oriented network abstraction. RETOS is a multithreaded operating system, hence it provides the commonly used thread model of programming interface to developers. We have used various implementation techniques to optimize the performance and resource usage of multithreading. RETOS also provides software solutions to separate kernel from user applications, and supports their robust execution on MMU-less hardware. The RETOS kernel can be dynamically reconfigured, via loadable kernel framework, so a applicationoptimized and resource-efficient kernel is constructed. Finally, the networking architecture in RETOS is designed with a layering concept to provide WSN-specific network abstraction. RETOS currently supports Atmel ATmega128, TI MSP430, and Chipcon CC2430 family of microcontrollers. Several real-world WSN applications are developed for RETOS and the overall evaluation of the systems is described in the paper

Enhancement of Human Hair Growth Using Ecklonia cava Polyphenols

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Background: Ecklonia cava is a brown alga that contains various compounds, including carotenoids, fucoidans, and phlorotannins. E. cava polyphenols (ECPs) are known to increase fibroblast survival. The human dermal papilla cell (hDPC) has the properties of mesenchymal-origin fibroblasts. Objective: This study aims to investigate the effect of ECPs on human hair growth promotion in vitro and ex vivo. Methods: MTT assays were conducted to examine the effect of ECPs on hDPC proliferation. Hair growth was measured using ex-vivo hair follicle cultures. Real-time polymerase chain reaction was performed to evaluate the mRNA expression of various growth factors in ECP-treated hDPCs. Results: Treatment with 10 μg/ml purified polyphenols from E. cava (PPE) enhanced the proliferation of hDPCs 30.3% more than in the negative control (p＜0.001). Furthermore, 0.1 μg/ml PPE extended the human hair shaft 30.8% longer than the negative control over 9 days (p＜0.05). Insulin-like growth factor-1 (IGF-1) mRNA expression increased 3.2-fold in hDPCs following treatment with 6 μg/ml PPE (p＜0.05). Vascular endothelial growth factor (VEGF) mRNA expression was also increased 2.0-fold by 3 μg/ml PPE (p＜0.05). Treatment with 10 μg/ml PPE reduced oxidative stress in hDPCs (p＜0.05). Conclusion: These results suggest that PPE could enhance human hair growth. This can be explained by hDPC proliferation coupled with increases in growth factors such as IGF-1 and VEGF. Reducing oxidative stress is also thought to help increase hDPCs. These favorable results suggest that PPE is a promising therapeutic candidate for hair loss.OAIID:oai:osos.snu.ac.kr:snu2016-01/102/0000045457/2ADJUST_YN:NEMP_ID:A079130DEPT_CD:801CITE_RATE:1.393FILENAME:ann dermatol 2016.pdfDEPT_NM:의학과SCOPUS_YN:YCONFIRM:

Comparison of the Gut Microbiota of Centenarians in Longevity Villages of South Korea with Those of Other Age Groups

Several studies have attempted to identify factors associated with longevity and maintenance of health in centenarians. In this study, we analyzed and compared the gut microbiota of centenarians in longevity villages with the elderly and adults in the same region and urbanized towns. Fecal samples were collected from centenarians, elderly, and young adults in longevity villages, and the gut microbiota sequences of elderly and young adults in urbanized towns of Korea were obtained from public databases. The relative abundance of Firmicutes was found to be considerably higher in subjects from longevity villages than those from urbanized towns, whereas Bacteroidetes was lower. Age-related rearrangement of gut microbiota was observed in centenarians, such as reduced proportions of Faecalibacterium and Prevotella, and increased proportion of Escherichia, along with higher abundances of Akkermansia, Clostridium, Collinsella, and uncultured Christensenellaceae. Gut microbiota of centenarians in rehabilitation hospitals were also different to those residing at home. These differences could be due to differences in diet patterns and living environments. In addition, phosphatidylinositol signaling system, glycosphingolipid biosynthesis, and various types of N-glycan biosynthesis were predicted to be higher in the gut microbiota of centenarians (corrected p < 0.05). These three metabolic pathways of gut microbiota can be associated with the immune status and healthy gut environment of centenarians. Although further studies are necessary to validate the function of microbiota between groups, this study provides valuable information on centenarians' gut microbiota.

Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: A comparative study

Previous studies have shown that topical steroid and shampoo containing zinc pyrithione provide clinical benefits for treatment of scalp seborrheic dermatitis. But the clinical efficacy of topical tacrolimus, a newly developed calcineurin inhibitor on seborrheic dermatitis, is not well investigated yet. We wanted to compare the clinical efficacy of topical tacrolimus with that of conventional treatment (zinc pyrithione shampoo and topical betamethasone) for treatment of seborrheic dermatitis of the scalp. Patients with seborrheic dermatitis of the scalp were randomly allocated to receive topical betamethasone, topical tacrolimus or zinc pyrithione shampoo. Some patients were instructed to continue the treatments for 8 weeks and the others to discontinue the treatments at week 4. We evaluated the efficacy using a clinical severity score, dandruff score and sebum secretion at baseline, week 4 and week 8. All treatment groups showed significant improvements in clinical assessment after 4 weeks. While the patients treated by zinc pyrithione improved continuously even after cessation of the treatment, the patients treated by betamethasone lotion or tacrolimus ointment were aggravated clinically. Topical tacrolimus was as effective as topical betamethasone, and showed more prolonged remission than topical betamethasone. To treat seborrheic dermatitis of the scalp, we think that the combination therapy of topical steroid or topical tacrolimus, and zinc pyrithione is recommended.Reygagne P, 2007, CUTIS, V79, P397Meingassner JG, 2005, EXP DERMATOL, V14, P752, DOI 10.1111/j.1600-0625.2005.00354.xRigopoulos D, 2004, BRIT J DERMATOL, V151, P1071, DOI 10.1111/j.1365-2133.2004.06208.xWolff K, 2004, EXPERT OPIN PHARMACO, V5, P643Meshkinpour A, 2003, J AM ACAD DERMATOL, V49, P145, DOI 10.1067/mjd.2003.450Milani M, 2003, CURR MED RES OPIN, V19, P342, DOI 10.1185/030079903125001875Nghiem P, 2002, J AM ACAD DERMATOL, V46, P228, DOI 10.1067/mjd.2002.120942Pierard-Franchimont C, 1998, J MYCOL MED, V8, P83Pari T, 1998, J EUR ACAD DERMATOL, V10, P89NAKAGAWA H, 1996, CLIN DRUG INVEST, V12, P245ERMOLAYEVA E, 1995, APPL ENVIRON MICROB, V61, P3385VANCUTSEM J, 1990, J AM ACAD DERMATOL, V22, P993